Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

Brent Appelman(Amsterdam University Medical Centers), A. H. Ayesha Lavell(Amsterdam University Medical Centers), Matthijs C. Brouwer(University of Amsterdam), Tom D. Y. Reijnders(Amsterdam University Medical Centers), Niels van Mourik(Inserm), Marit J. van Gils(Amsterdam University Medical Centers), Alex R. Schuurman(Amsterdam Neuroscience), Marije K. Bomers, Marleen A. Slim(Amsterdam University Medical Centers), W. Joost Wiersinga(Amsterdam Neuroscience), Sabine E. Olie(Amsterdam Neuroscience), Jonne J. Sikkens(Amsterdam University Medical Centers), Judith A. Burger(Amsterdam University Medical Centers), Yvo M. Smulders(Amsterdam University Medical Centers), Karlijn van der Straten(Amsterdam University Medical Centers), Lonneke A. van Vught(University of Amsterdam), Justin de Brabander, Nora Chekrouni(Inserm), Alexander P. J. Vlaar(University of Amsterdam), Menno D. de Jong(National Institute for Public Health and the Environment), Melissa Oomen(Amsterdam University Medical Centers), David T. P. Buis, Michiel Schinkel, Rogier W. Sanders(Scripps Research Institute), Khadija Tejjani(Cancer Center Amsterdam), Diederik van de Beek(University of Amsterdam), Edgar Peters(Psychotherapy & Movement), Meliawati Poniman(Amsterdam University Medical Centers), AH Ayesha Lavell(Amsterdam University Medical Centers)
EBioMedicine
September 24, 2021
Cited by 22


Related Papers